Search Results - "GROENEWEGEN, G"

Use of tunable nanopore blockade rates to investigate colloidal dispersions by Willmott, G R, Vogel, R, Yu, S S C, Groenewegen, L G, Roberts, G S, Kozak, D, Anderson, W, Trau, M

“…Tunable nanopores fabricated in elastomeric membranes have been used to study the dependence of ionic current blockade rate on the concentration and…”
Get more information

Long term disease control and abscopal effects by stereotactic radiotherapy for growing metastases during anti-PD1 by Suijkerbuijk, K.P., El Sharouni, S.Y., Damen, P.P., Lindert, A.V., Groenewegen, G., Verhoeff, J.J.C.

Get full text

Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma by Groenewegen, G, Walraven, M, Vermaat, J, de Gast, B, Witteveen, E, Giles, R, Haanen, J, Voest, E

“…Background: The endothelin system is involved in tumour growth. Atrasentan, a selective endothelin-A-receptor antagonist, blocks endothelin signalling. This…”
Get full text

Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies by Jayson, Gordon C., Zweit, Jamal, Jackson, Alan, Mulatero, Clive, Julyan, Peter, Ranson, Malcolm, Broughton, Lynn, Wagstaff, John, Hakannson, Leif, Groenewegen, Gerard, Bailey, John, Smith, Nigel, Hastings, David, Lawrance, Jeremy, Haroon, Hamied, Ward, Tim, McGown, Alan T., Tang, Meina, Levitt, Dan, Marreaud, Sandrine, Lehmann, Frederic F., Herold, Manfred, Zwierzina, Heinz

“…Background: Vascular endothelial growth factor (VEGF) is a potent angiogenic cytokine, and various inhibitory agents, including specific antibodies, have been…”
Get full text

Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models by Vermaat, J.S., van der Tweel, I., Mehra, N., Sleijfer, S., Haanen, J.B., Roodhart, J.M., Engwegen, J.Y., Korse, C.M., Langenberg, M.H., Kruit, W., Groenewegen, G., Giles, R.H., Schellens, J.H., Beijnen, J.H., Voest, E.E.

“…In metastatic renal cell cancer (mRCC), the Memorial Sloan-Kettering Cancer Center (MSKCC) risk model is widely used for clinical trial design and patient…”
Get full text

Incidence of metachronous contralateral testicular germ cell tumour and association with chemotherapy by Blok, J.M., Groot, H.J., Huele, E.H., De Wit, R., Gietema, J.A., Groenewegen, G., Witjes, J.A., Van Den Berg, H.A., Nuver, J., Tromp, J.M., De Brouwer, P.J.M., Smilde, T.J., Aarts, M.J.B., Vanneste, B.G.L., Bosch, J.L.H.R., Horenblas, S., Schaapveld, M., Meijer, R.P.

Get full text

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer by Rea, D. W., Nortier, J. W. R., Ten Bokkel Huinink, W. W., Falk, S., Richel, D. J., Maughan, T., Groenewegen, G., Smit, J. M., Steven, N., Bakker, J. M., Semiond, D., Kerr, D. J., Punt, C. J. A.

“…Purpose:: The aim of this study was to determine in patients with previously untreated advanced colorectal cancer the maximum tolerated dose (MTD) and safety…”
Get full text

Tumor Angiogenesis Is Accompanied by a Decreased Inflammatory Response of Tumor-Associated Endothelium by Griffioen, Arjan W., Damen, Cora A., Blijham, Geert H., Groenewegen, Gerard

“…We previously showed that endothelial cells (EC) from the vasculature of human solid tumors have a decreased expression of intercellular adhesion molecule-1…”
Get full text

Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer by Jayson, Gordon C., Mulatero, Clive, Ranson, Malcolm, Zweit, Jamal, Jackson, Alan, Broughton, Lynn, Wagstaff, John, Hakansson, Leif, Groenewegen, Gerard, Lawrance, Jeremy, Tang, Meina, Wauk, Linda, Levitt, Dan, Marreaud, Sandrine, Lehmann, Frederic F., Herold, Manfred, Zwierzina, Heinz

“…We assessed the tolerability, safety, pharmacokinetics and dose-limiting toxicity (DLT) of the recombinant humanized IgG4 anti-vascular endothelial growth…”
Get full text

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-Fc RI × anti-HER-2 neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer by REPP, R, VAN OJIK, H. H, DEO, Y. M, BLIJHAM, G. H, KALDEN, J. R, DE WINKEL, J. G. J. Van, GRAMATZKI, M, VALERIUS, T, GROENEWEGEN, G, WIELAND, G, OETZEL, C, STOCKMEYER, B, BECKER, W, EISENHUT, M, STEININGER, H

“…A phase I study of the bispecific antibody MDX-H210 in combination with granulocyte colony-stimulating factor (G-CSF) was performed in stage IV breast…”
Get full text

Impact of integration of clinical and outpatient units on cancer patient satisfaction by Wessels, H., de Graeff, A., Groenewegen, G., Wynia, K., de Heus, M., Vos, J.B.H., Tjia, P., Kruitwagen, C.L.J.J., Teunissen, S.C.C.M., Voest, Emile E.

“…Objective There is an ongoing drive to measure and improve quality of care. Donabedians' quality framework with structure, process and outcome domains provides…”
Get full text

Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin by TERWOGT, Jetske M, GROENEWEGEN, Gerard, BEIJNEN, Jos H, SCHELLENS, Jan H. M, PLUIM, Dick, MALIEPAARD, Marc, TIBBEN, Matthijs M, HUISMAN, Albert, TEN BOKKEL HUININK, Wim W, SCHOT, Margaret, WELBANK, Helen, VOEST, Emile E

“…To investigate the safety and pharmacokinetics of a new liposomal formulation of cisplatin, SPI-77, in patients with advanced malignancies. Patients with…”
Get full text

POS-03.53: Complications and survival in patients with retroperitoneal lymph node dissection (RPLND) after chemotherapy for testicular cancer in a medium volume referral centre by Boeken Kruger, A, Richardson, R, Lock, T, Groenewegen, G, Bosch, R

Get full text

Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma by VERRA, N, JANSEN, R, DE WAAL, M, HORENBLAS, S, DE GAST, G. C, GROENEWEGEN, G, MALLO, H, KERSTEN, M. J, BEX, A, VYTH-DREESE, F. A, SEIN, J, VAN DE KASTEELE, W, NOOIJEN, W. J

“…The purpose of the study was to determine toxicity, efficacy and immunologic effects of concurrent subcutaneous injections of low-dose interleukin-2 (LD-IL-2),…”
Get full text

Immunochemotherapy with interleukin-2, interferon-α and 5-fluorouracil for progressive metastatic renal cell carcinoma : a multicenter phase II study by VAN HERPEN, C. M. L, JANSEN, R. L. H, KRUIT, W. H. J, HOEKMAN, K, GROENEWEGEN, G, OSANTO, S, DE MULDER, P. H. M

“…In patients with metastatic renal cell carcinoma response rates of 7-26% have been achieved with immunotherapy. A high response rate of 48% in 35 patients has…”
Get full text

Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha by GROENEWEGEN, Gerard, BLOEM, Andries, DE GAST, Gijsbert C

“…A regimen of sequential chemoimmunotherapy (SCIT) was studied in a phase I/II study to analyze toxicity, anti-tumor and immunomodulatory effects in patients…”
Get full text

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks by KERBUSCH, T, GROENEWEGEN, G, BEIJNEN, J. H, SCHELLENS, J. H. M, MATHOT, R. A. A, HERBEN, V. M. M, TEN BOKKEL HUININK, W. W, SWART, M, AMBAUM, B, ROSING, H, JANSEN, S, VOEST, E. E

“…To determine the maximum-tolerated dose (MTD), dose-limiting toxicities, and pharmacokinetics of topotecan administered as a 30-min intravenous (i.v.) infusion…”
Get full text

GM-CSF can cause T cell activation; results of sequential chemo-immunotherapy by Groenewegen, G, de Gast, G.C

Get full text

1204PLong term disease control and abscopal effects by stereotactic radiotherapy for growing metastases during anti-PD1 by Suijkerbuijk, K P, El Sharouni, S Y, Damen, P P, Lindert, A V, Groenewegen, G, Verhoeff, J J C

Get full text

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial by Eggermont, Alexander MM, Suciu, Stefan, MacKie, Rona, Ruka, Wlodzimierz, Testori, Alessandro, Kruit, Wim, Punt, Cornelis JA, Delauney, Michelle, Sales, François, Groenewegen, Gerard, Ruiter, Dirk J, Jagiello, Izabella, Stoitchkov, Konstantin, Keilholz, Ulrich, Lienard, Danielle

“…Individuals affected by melanoma with thick primary tumours or regional node involvement have a poor outlook, with only 30–50% alive at 5 years. High-dose and…”
Get full text